German biotech firm CureVac AG has agreed to an alliance with drugmaker Bayer AG to help it seek regulatory approval for its experimental COVID-19 vaccine and distribute doses, the two companies said yesterday.
“Bayer will contribute its expertise and established infrastructure in areas such as clinical operations, regulatory affairs, pharmacovigilance, medical information, supply chain performance as well as support in selected countries,” they said.
Financial terms were not disclosed.
Photo: Reuters
CureVac, which had said it was looking for a larger partner, last month started a late-stage clinical trial of its COVID-19 vaccine candidate, banking on the same technology that has allowed rivals BioNTech and Moderna to lead the development race.
The tie-up echoes a similar deal by German peer BioNTech SE, also a research-focused biotech firm, which last year agreed to collaborate with global pharma giant Pfizer Inc on its vaccine, which is now being rolled out globally.
CureVac, which is listed on the NASDAQ, and backed by investors Dietmar Hopp, the Gates Foundation, GlaxoSmithKline PLC and the German government, has said that it aims to produce up to 300 million doses of the vaccine this year and up to 600 million next year.
In March last year, CureVac was at the center of a row over alleged attempts by US President Donald Trump to gain access to the vaccine, but the company denied at the time having received any US offers for the company or its assets.
As it awaits regulatory approval, the EU has secured up to 405 million doses of the immunization, among a slew of supply deals agreed between the bloc and other vaccine developers.
Bayer’s pharma unit, which is trying to build a new cell and gene therapy business, has expertise in cancer, hemophilia, multiple sclerosis, cardiovascular diseases and women’s health, but not in vaccines.
The group’s stock has been battered by writedowns at its agriculture division, litigation woes and a bleaker profit outlook, in large part related to its US$63 billion takeover of seed maker Monsanto Co.
Intel Corp chief executive officer Lip-Bu Tan (陳立武) is expected to meet with Taiwanese suppliers next month in conjunction with the opening of the Computex Taipei trade show, supply chain sources said on Monday. The visit, the first for Tan to Taiwan since assuming his new post last month, would be aimed at enhancing Intel’s ties with suppliers in Taiwan as he attempts to help turn around the struggling US chipmaker, the sources said. Tan is to hold a banquet to celebrate Intel’s 40-year presence in Taiwan before Computex opens on May 20 and invite dozens of Taiwanese suppliers to exchange views
Application-specific integrated circuit designer Faraday Technology Corp (智原) yesterday said that although revenue this quarter would decline 30 percent from last quarter, it retained its full-year forecast of revenue growth of 100 percent. The company attributed the quarterly drop to a slowdown in customers’ production of chips using Faraday’s advanced packaging technology. The company is still confident about its revenue growth this year, given its strong “design-win” — or the projects it won to help customers design their chips, Faraday president Steve Wang (王國雍) told an online earnings conference. “The design-win this year is better than we expected. We believe we will win
Chizuko Kimura has become the first female sushi chef in the world to win a Michelin star, fulfilling a promise she made to her dying husband to continue his legacy. The 54-year-old Japanese chef regained the Michelin star her late husband, Shunei Kimura, won three years ago for their Sushi Shunei restaurant in Paris. For Shunei Kimura, the star was a dream come true. However, the joy was short-lived. He died from cancer just three months later in June 2022. He was 65. The following year, the restaurant in the heart of Montmartre lost its star rating. Chizuko Kimura insisted that the new star is still down
While China’s leaders use their economic and political might to fight US President Donald Trump’s trade war “to the end,” its army of social media soldiers are embarking on a more humorous campaign online. Trump’s tariff blitz has seen Washington and Beijing impose eye-watering duties on imports from the other, fanning a standoff between the economic superpowers that has sparked global recession fears and sent markets into a tailspin. Trump says his policy is a response to years of being “ripped off” by other countries and aims to bring manufacturing to the US, forcing companies to employ US workers. However, China’s online warriors